Your browser doesn't support javascript.
loading
HIV-1 neutralizing antibodies elicited in humans by a prefusion-stabilized envelope trimer form a reproducible class targeting fusion peptide.
Wang, Shuishu; Matassoli, Flavio; Zhang, Baoshan; Liu, Tracy; Shen, Chen-Hsiang; Bylund, Tatsiana; Johnston, Timothy; Henry, Amy R; Teng, I-Ting; Tripathi, Prabhanshu; Becker, Jordan E; Changela, Anita; Chaudhary, Ridhi; Cheng, Cheng; Gaudinski, Martin; Gorman, Jason; Harris, Darcy R; Lee, Myungjin; Morano, Nicholas C; Novik, Laura; O'Dell, Sijy; Olia, Adam S; Parchment, Danealle K; Rawi, Reda; Roberts-Torres, Jesmine; Stephens, Tyler; Tsybovsky, Yaroslav; Wang, Danyi; Van Wazer, David J; Zhou, Tongqing; Doria-Rose, Nicole A; Koup, Richard A; Shapiro, Lawrence; Douek, Daniel C; McDermott, Adrian B; Kwong, Peter D.
Afiliação
  • Wang S; Vaccine Research Center, National Institutes of Health, Bethesda, MD 20892, USA.
  • Matassoli F; Vaccine Research Center, National Institutes of Health, Bethesda, MD 20892, USA.
  • Zhang B; Vaccine Research Center, National Institutes of Health, Bethesda, MD 20892, USA.
  • Liu T; Vaccine Research Center, National Institutes of Health, Bethesda, MD 20892, USA.
  • Shen CH; Vaccine Research Center, National Institutes of Health, Bethesda, MD 20892, USA.
  • Bylund T; Vaccine Research Center, National Institutes of Health, Bethesda, MD 20892, USA.
  • Johnston T; Vaccine Research Center, National Institutes of Health, Bethesda, MD 20892, USA.
  • Henry AR; Vaccine Research Center, National Institutes of Health, Bethesda, MD 20892, USA.
  • Teng IT; Vaccine Research Center, National Institutes of Health, Bethesda, MD 20892, USA.
  • Tripathi P; Vaccine Research Center, National Institutes of Health, Bethesda, MD 20892, USA.
  • Becker JE; Zuckerman Mind Brain Behavior Institute, Columbia University, New York, NY 10027, USA; Department of Biochemistry and Molecular Biophysics, Columbia University Vagelos College of Physicians and Surgeons, New York, NY 10032, USA.
  • Changela A; Vaccine Research Center, National Institutes of Health, Bethesda, MD 20892, USA.
  • Chaudhary R; Vaccine Research Center, National Institutes of Health, Bethesda, MD 20892, USA.
  • Cheng C; Vaccine Research Center, National Institutes of Health, Bethesda, MD 20892, USA.
  • Gaudinski M; Vaccine Research Center, National Institutes of Health, Bethesda, MD 20892, USA.
  • Gorman J; Vaccine Research Center, National Institutes of Health, Bethesda, MD 20892, USA.
  • Harris DR; Vaccine Research Center, National Institutes of Health, Bethesda, MD 20892, USA.
  • Lee M; Vaccine Research Center, National Institutes of Health, Bethesda, MD 20892, USA.
  • Morano NC; Zuckerman Mind Brain Behavior Institute, Columbia University, New York, NY 10027, USA; Department of Biochemistry and Molecular Biophysics, Columbia University Vagelos College of Physicians and Surgeons, New York, NY 10032, USA.
  • Novik L; Vaccine Research Center, National Institutes of Health, Bethesda, MD 20892, USA.
  • O'Dell S; Vaccine Research Center, National Institutes of Health, Bethesda, MD 20892, USA.
  • Olia AS; Vaccine Research Center, National Institutes of Health, Bethesda, MD 20892, USA.
  • Parchment DK; Vaccine Research Center, National Institutes of Health, Bethesda, MD 20892, USA.
  • Rawi R; Vaccine Research Center, National Institutes of Health, Bethesda, MD 20892, USA.
  • Roberts-Torres J; Vaccine Research Center, National Institutes of Health, Bethesda, MD 20892, USA.
  • Stephens T; Electron Microscopy Laboratory, Cancer Research Technology Program, Frederick National Laboratory for Cancer Research, Frederick, MD 21701, USA.
  • Tsybovsky Y; Electron Microscopy Laboratory, Cancer Research Technology Program, Frederick National Laboratory for Cancer Research, Frederick, MD 21701, USA.
  • Wang D; Vaccine Research Center, National Institutes of Health, Bethesda, MD 20892, USA.
  • Van Wazer DJ; Vaccine Research Center, National Institutes of Health, Bethesda, MD 20892, USA.
  • Zhou T; Vaccine Research Center, National Institutes of Health, Bethesda, MD 20892, USA.
  • Doria-Rose NA; Vaccine Research Center, National Institutes of Health, Bethesda, MD 20892, USA.
  • Koup RA; Vaccine Research Center, National Institutes of Health, Bethesda, MD 20892, USA.
  • Shapiro L; Zuckerman Mind Brain Behavior Institute, Columbia University, New York, NY 10027, USA; Department of Biochemistry and Molecular Biophysics, Columbia University Vagelos College of Physicians and Surgeons, New York, NY 10032, USA.
  • Douek DC; Vaccine Research Center, National Institutes of Health, Bethesda, MD 20892, USA.
  • McDermott AB; Vaccine Research Center, National Institutes of Health, Bethesda, MD 20892, USA.
  • Kwong PD; Vaccine Research Center, National Institutes of Health, Bethesda, MD 20892, USA; Department of Biochemistry and Molecular Biophysics, Columbia University Vagelos College of Physicians and Surgeons, New York, NY 10032, USA. Electronic address: pdkwong@nih.gov.
Cell Rep ; 42(7): 112755, 2023 07 25.
Article em En | MEDLINE | ID: mdl-37436899
ABSTRACT
Elicitation of antibodies that neutralize the tier-2 neutralization-resistant isolates that typify HIV-1 transmission has been a long-sought goal. Success with prefusion-stabilized envelope trimers eliciting autologous neutralizing antibodies has been reported in multiple vaccine-test species, though not in humans. To investigate elicitation of HIV-1 neutralizing antibodies in humans, here, we analyze B cells from a phase I clinical trial of the "DS-SOSIP"-stabilized envelope trimer from strain BG505, identifying two antibodies, N751-2C06.01 and N751-2C09.01 (named for donor-lineage.clone), that neutralize the autologous tier-2 strain, BG505. Though derived from distinct lineages, these antibodies form a reproducible antibody class that targets the HIV-1 fusion peptide. Both antibodies are highly strain specific, which we attribute to their partial recognition of a BG505-specific glycan hole and to their binding requirements for a few BG505-specific residues. Prefusion-stabilized envelope trimers can thus elicit autologous tier-2 neutralizing antibodies in humans, with initially identified neutralizing antibodies recognizing the fusion-peptide site of vulnerability.
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Infecções por HIV / HIV-1 / Soropositividade para HIV / Vacinas contra a AIDS Limite: Humans Idioma: En Revista: Cell Rep Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Estados Unidos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Infecções por HIV / HIV-1 / Soropositividade para HIV / Vacinas contra a AIDS Limite: Humans Idioma: En Revista: Cell Rep Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Estados Unidos